Literature DB >> 12498716

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.

Olga V Volpert1, Roberto Pili, Hashmat A Sikder, Thomas Nelius, Tetiana Zaichuk, Chad Morris, Clinton B Shiflett, Meghann K Devlin, Katherine Conant, Rhoda M Alani.   

Abstract

Id proteins are helix-loop-helix transcription factors that regulate tumor angiogenesis. In order to identify downstream effectors of Id1 involved in the regulation of angiogenesis, we performed PCR-select subtractive hybridization on wild-type and Id1 knockout mouse embryo fibroblasts (MEFs). Here we demonstrate that thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis, is a target of transcriptional repression by Id1. We also show that Id1-null MEFs secrete an inhibitor of endothelial cell migration, which is completely inactivated by depletion of TSP-1. Furthermore, in vivo studies revealed decreased neovascularization in matrigel assays in Id1-null mice compared to their wild-type littermates. This decrease was completely reversed by a TSP-1 neutralizing antibody. We conclude that TSP-1 is a major target for Id1 effects on angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498716     DOI: 10.1016/s1535-6108(02)00209-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  57 in total

1.  Activation of the transforming growth factor beta pathway in bacterial otitis media.

Authors:  Yun-Woo Lee; Yunju Chung; Steven K Juhn; Youngki Kim; Jizhen Lin
Journal:  Ann Otol Rhinol Laryngol       Date:  2011-03       Impact factor: 1.547

2.  Cell-nonautonomous function of Id1 in the hematopoietic progenitor cell niche.

Authors:  Hyung Chan Suh; Ming Ji; John Gooya; Michael Lee; Kimberly D Klarmann; Jonathan R Keller
Journal:  Blood       Date:  2009-05-28       Impact factor: 22.113

3.  A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.

Authors:  Robert C Doebele; Frank T Schulze-Hoepfner; Jia Hong; Alexandre Chlenski; Benjamin D Zeitlin; Kushboo Goel; Suzana Gomes; Yuru Liu; Mark K Abe; Jacques E Nor; Mark W Lingen; Marsha Rich Rosner
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

4.  Effects of detraining on the temporal expression of positive and negative angioregulatory proteins in skeletal muscle of mice.

Authors:  Sara A Olenich; Gerald N Audet; Kathleen A Roberts; I Mark Olfert
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

5.  Role of inhibitor of DNA binding-1 protein is related to angiogenesis in the tumor advancement of uterine endometrial cancers.

Authors:  Min Khine Maw; Jiro Fujimoto; Teruhiko Tamaya
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

6.  Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma.

Authors:  Megan A Healey; Staci L Deaton; Jonathan K Alder; Véronique Winnepenninckx; Robert A Casero; James G Herman
Journal:  Epigenetics       Date:  2010-07-01       Impact factor: 4.528

Review 7.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

8.  Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

Authors:  Alexander Zaslavsky; Kwan-Hyuck Baek; Ryan C Lynch; Sarah Short; Jenny Grillo; Judah Folkman; Joseph E Italiano; Sandra Ryeom
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

9.  Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta.

Authors:  Karen O Yee; Michael Streit; Thomas Hawighorst; Michael Detmar; Jack Lawler
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers.

Authors:  Min Khine Maw; Jiro Fujimoto; Teruhiko Tamaya
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.